RxDoctor Payments Data

Lee Musher, MD

Geriatric Medicine · Chevy Chase, MDNPI 1437281961

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $9,520 of the $12,537 with a category attached, or 75.9%. Tersera Therapeutics LLC accounts for 74.1% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $9,551 and has fallen 98.2% since, to $173 in 2025. Among geriatric medicine clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,537in general payments, 2019–2025

Across 42 payments — averaging $298.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tersera Therapeutics LLC$9K
  • Pfizer$2K
  • Otsuka America Pharmaceutical, Inc.$227
  • AbbVie$225
  • Novo Nordisk$186
  • Aerin Medical Inc.$144
  • plus $574 from 8 others

What the payments were for

  • Consulting fees$9,52076%
  • Speaking & faculty fees$1,68013%
  • Food & beverage$1,33711%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,537 in reported general payments places this provider in the 95th percentile of 112 geriatric medicine providers in Maryland.

See all geriatric medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$82,751
Medicare patients
150
Services billed
626

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban53$28,569
MounjaroTirzepatide25$26,222
OzempicSemaglutide33$25,928
SynthroidLevothyroxine Sodium26$2,490
Atorvastatin Calcium96$1,281
Levothyroxine Sodium71$1,114
Metoprolol Succinate62$933
Esomeprazole Magnesium28$812
Rosuvastatin Calcium61$804
Gabapentin32$759
Amlodipine Besylate84$708
Memantine Hcl27$688
Tamsulosin Hcl33$638
Alprazolam42$628
Lisinopril80$577

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,888$28,56953 claims
Novo NordiskOzempic$186$25,92833 claims
AbbVieSynthroid$225$2,49026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 112 geriatric medicine providers in Maryland.

Other geriatric medicine in Chevy Chase

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →